Suppr超能文献

喉癌诱导化疗后贫血与中性粒细胞与淋巴细胞比值变化

Anemia and neutrophil-to-lymphocyte ratio in laryngeal cancer treated with induction chemotherapy.

机构信息

Department of Head and Neck Oncology, Gustave Roussy Institute, University of Paris-Saclay, Villejuif, France.

Department of Radiology, Gustave Roussy Institute, University of Paris-Saclay, Villejuif, France.

出版信息

Laryngoscope. 2020 Apr;130(4):E144-E150. doi: 10.1002/lary.28021. Epub 2019 Apr 22.

Abstract

OBJECTIVES/HYPOTHESIS: We studied the influence of the neutrophil-to-lymphocyte ratio (NLR) and anemia on the response to induction chemotherapy (IC) and survival outcomes in laryngeal cancer patients treated with a preservation protocol.

STUDY DESIGN

Retrospective single-center case series.

METHODS

We analyzed patients with T3 laryngeal cancer treated with IC using a preservation protocol. The NLR and hemoglobin levels were assessed before treatment and after IC. The response to chemotherapy was assessed using Response Evaluation Criteria in Solid Tumours 1.1 and World Heath Organization standards. The oncological endpoints were overall survival (OS) and disease-free survival (DFS).

RESULTS

Sixty-eight patients were analyzed. The median NLR and hemoglobin levels before and after IC were 2.76 and 14.5 g/dL, and 2.01 and 11.6 g/dL, respectively. The NLR and anemia before treatment were not correlated, and they were not associated with the response to chemotherapy. However, an NLR > 5 and anemia before treatment were both associated with shorter OS and DFS. Notably, they were the only factors found to be significantly associated with survival outcomes.

CONCLUSIONS

In laryngeal cancer, patients treated with a preservation protocol, a high NLR ratio, and anemia before IC were associated with shorter survival, independently of the response to chemotherapy.

LEVEL OF EVIDENCE

4 Laryngoscope, 130:E144-E150, 2020.

摘要

目的/假设:我们研究了中性粒细胞与淋巴细胞比值(NLR)和贫血对采用保留方案治疗的喉癌患者诱导化疗(IC)反应和生存结果的影响。

研究设计

回顾性单中心病例系列研究。

方法

我们分析了采用 IC 保留方案治疗的 T3 喉癌患者。在治疗前和 IC 后评估 NLR 和血红蛋白水平。使用实体瘤反应评估标准 1.1 和世界卫生组织标准评估化疗反应。肿瘤学终点是总生存期(OS)和无病生存期(DFS)。

结果

共分析了 68 例患者。IC 前后 NLR 和血红蛋白的中位数分别为 2.76 和 14.5 g/dL,2.01 和 11.6 g/dL。治疗前的 NLR 和贫血无相关性,与化疗反应无关。然而,治疗前 NLR > 5 和贫血均与 OS 和 DFS 较短相关。值得注意的是,它们是唯一与生存结果显著相关的因素。

结论

在采用保留方案治疗的喉癌患者中,IC 前 NLR 比值高和贫血与生存时间较短有关,与化疗反应无关。

证据水平

4《喉镜》,130:E144-E150,2020 年。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验